Organoid DRUG-seq service
Organoid DRUG-seq boosts screening efforts based on gene expression profiling of organoids by offering a unique RNA-seq service that is highly sensitive, extraction-free, massively multiplexed and extremely cost-effective.
Organoid DRUG-seq boosts screening efforts based on gene expression profiling of organoids by offering a unique RNA-seq service that is highly sensitive, extraction-free, massively multiplexed and extremely cost-effective.
The MERCURIUS™ Organoid DRUG-seq service offers the most comprehensive, high-throughput and cost-efficient solution for gene expression analysis projects starting from 3D organoids or spheroids.
Optional downstream differential gene expression analysis is also available upon request.
Step 1
Step 2
Step 3
Step 4
(Qubit, Fragment analyzer, shallow sequencing)
1 week
Step 5
Step 6
1 week
Step 7
Number of samples:
12
Reads per sample in demo dataset:
10'000 reads
To have access to the deep-sequenced dataset (24.5M reads per sample) contact us.
Demo dataset file size:
7.16 MB
To guarantee high quality data, we normally request that each sample contains 5k-50k cells/well for 96 well-plate or 2k-10k cells/well for 384 well-plate. The minimum number of cells per pool is 80k.
Organoid DRUG-seq is 3’-end RNA sequencing method and, as such, requires significantly less sequencing as compared to standard full-length RNA-seq in order to reach accurate gene quantification. We therefore normally recommend sequencing between 1 to 10 million reads for each sample, which enables the reliable and unbiased detection of over 18’000 genes.
As part of our standard service pipeline, we align the generated data to the genome of choice, provide a detailed report on the alignment and gene counting statistics and, finally, provide ready-to-use gene count matrices for downstream analysis.
Explore the latest, relevant publications in the industry to learn more about our technologies.
Book a one-on-one call with one of our RNA experts to discover how we can assist your next project.
Receive email updates on our latest products and services, news and event updates and more. No ads, no spam.